In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy

REFERENCES

• American Cancer Society. Cancer Facts and Figures 2005. [http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Last Accessed: 1 June 2009.]
   Google Scholar
• Bosetti, C.; Bertuccio, P.; Levi, F.; Lucchini, F.; Negri, E.; La Vecchia, C. Cancer mortality in the European Union, 1970–2003, with a joinpoint analysis. Ann Oncol 2008, 19(4), 631–640.
   PubMed Web of Science ®Google Scholar
• De Vita, V.T.; Heliman, S.; Rosenberg, S.A. Cancer: Principles & Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins, 2008.
   Google Scholar
• Greenberg, P.A.; Hortobagyi, G.N.; Smith, T.L.; Ziegler, L.D.; Frye, D.K.; Buzdar, A.U. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996, 14(8), 2197–2205.
   PubMed Web of Science ®Google Scholar
• Bruzzi, P.; Del Mastro, L.; Sormani, M.P.; Bastholt, L.; Danova, M.; Focan, C.; Fountzilas, G.; Paul, J.; Rosso, R.; Venturini, M. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 2005, 23(22), 5117–5125.
   PubMed Web of Science ®Google Scholar
• Tanner, M.; Isola, J.; Wiklund, T.; Erikstein, B.; Kellokumpu-Lehtinen, P.; Malmström, P.; Wilking, N.; Nilsson, J.; Bergh, J. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006, 24(16), 2428–2436.
   PubMed Web of Science ®Google Scholar
• Galmarini, C.M.; Treilleux, I.; Cardoso, F.; Bernard-Marty, C.; Durbecq, V.; Gancberg, D.; Bissery, M.C.; Paesmans, M.; Larsimont, D.; Piccart, M.J.; Di Leo, A.; Dumontet, C. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res 2008, 14(14), 4511–4516.
   PubMed Web of Science ®Google Scholar
• Albain, K.S.; Nag, S.M.; Calderillo-Ruiz, G.; Jordaan, J.P.; Llombart, A.C.; Pluzanska, A.; Rolski, J.; Melemed, A.S.; Reyes-Vidal, J.M.; Sekhon, J.S.; Simms, L.; O'Shaughnessy, J. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008, 26(24), 3950–3957.
   PubMed Web of Science ®Google Scholar
• Lund, B.; Kristjansen, P.E.; Hansen, H.H. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 1993, 19(1), 45–55.
   PubMed Web of Science ®Google Scholar
• Davidson, J.D.; Ma, L.; Flagella, M.; Geeganage, S.; Gelbert, L.M.; Slapak, C.A. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004, 64(11), 3761–3766.
   PubMed Web of Science ®Google Scholar
• Bergman, A.M.; Eijk, P.P.; Ruiz van Haperen, V.W.; Smid, K.; Veerman, G.; Hubeek, I.; van den Ijssel, P.; Ylstra, B.; Peters, G.J. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005, 65(20), 9510–9516.
   PubMed Web of Science ®Google Scholar
• Bepler, G.; Kusmartseva, I.; Sharma, S.; Gautam, A.; Cantor, A.; Sharma, A.; Simon, G. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006, 24(29), 4731–4737.
   PubMed Web of Science ®Google Scholar
• Nakahira, S.; Nakamori, S.; Tsujie, M.; Takahashi, Y.; Okami, J.; Yoshioka, S.; Yamasaki, M.; Marubashi, S.; Takemasa, I.; Miyamoto, A.; Takeda, Y.; Nagano, H.; Dono, K.; Umeshita, K.; Sakon, M.; Monden, M. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 2007, 120(6), 1355–1363.
   PubMed Web of Science ®Google Scholar
• Zheng, Z.; Chen, T.; Li, X.; Haura, E.; Sharma, A.; Bepler, G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007, 356(8), 800–808.
   PubMed Web of Science ®Google Scholar
• Simon, G.; Sharma, A.; Li, X.; Hazelton, T.; Walsh, F.; Williams, C.; Chiappori, A.; Haura, E.; Tanvetyanon, T.; Antonia, S.; Cantor, A.; Bepler, G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007, 25(19), 2741–2746.
   PubMed Web of Science ®Google Scholar
• Rosell, R.; Danenberg, K.D.; Alberola, V.; Bepler, G.; Sanchez, J.J.; Camps, C.; Provencio, M.; Isla, D.; Taron, M.; Diz, P.; Artal, A. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004, 10(4), 1318–1325.
   PubMed Web of Science ®Google Scholar
• Ceppi, P.; Volante, M.; Novello, S.; Rapa, I.; Danenberg, K.S.; Danenberg, P.V.; Cambieri, A.; Selvaggi, G.; Saviozzi, S.; Calogero, R.; Papotti, M.; Scagliotti, G.V. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006, 17(12), 1818–1825.
   PubMed Web of Science ®Google Scholar
• Rosell, R.; Skrzypski, M.; Jassem, E.; Taron, M.; Bartolucci, R.; Sanchez, J.J.; Mendez, P.; Chaib, I.; Perez-Roca, L.; Szymanowska, A.; Rzyman, W.; Puma, F.; Kobierska-Gulida, G.; Farabi, R.; Jassem, J. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007, 2(11), e1129.
   PubMedGoogle Scholar
• James, C.R.; Quinn, J.E.; Mullan, P.B.; Johnston, P.G.; Harkin, D.P. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 2007, 12(2), 142–150.
   PubMed Web of Science ®Google Scholar
• Camp, R.L.; Chung, G.G.; Rimm, D.L. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002, 8(11), 1323–1327.
   PubMed Web of Science ®Google Scholar
• Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; van Glabbeke, M.; van Oosterom, A.T.; Christian, M.C.; Gwyther, S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3), 205–216.
   PubMed Web of Science ®Google Scholar
• Toschi, L.; Finocchiaro, G.; Bartolini, S.; Gioia, V.; Cappuzzo, F. Role of gemcitabine in cancer therapy. Future Oncol 2005, 1(1), 7–17.
   PubMedGoogle Scholar
• Olaussen, K.A.; Dunant, A.; Fouret, P.; Brambilla, E.; Andre, F.; Haddad, V.; Taranchon, E.; Filipts, M.; Pirker, R.; Popper, H.H.; Stahel, R.; Sabatier, L.; Pignon, J.P.; Tursz, T.; Le Chevalier, T.; Soria, J.C. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355(10), 983–991.
   PubMed Web of Science ®Google Scholar
• Taron, M.; Rosell, R.; Felip, E.; Mendez, P.; Souglakos, J.; Ronco, M.S.; Queralt, C.; Majo, J.; Sanchez, J.M.; Sanchez, J.J.; Maestre, J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004, 13(20), 2443–2449.
   PubMed Web of Science ®Google Scholar
• Chappuis, P.O.; Goffin, J.; Wong, N.; Perret, C.; Ghadirian, P.; Tonin, P.N.; Foulkes, W.D. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002, 39(8), 608–610. .
   PubMed Web of Science ®Google Scholar
• Goffin, J.R.; Chappuis, P.O.; Bégin, L.R.; Wong, N.; Brunet, J.S.; Hamel, N.; Paradis, A.J.; Boyd, J.; Foulkes, W.D. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 2003, 97(3), 527–536.
   PubMed Web of Science ®Google Scholar
• Byrski, T.; Huzarski, T.; Dent, R.; Gronwald, J.; Zuziak, D.; Cybulski, C.; Kladny, J.; Gorski, B.; Lubinski, J.; Narod, S.A. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009, 1115(2), 359–363.
   Google Scholar
• Bepler, G.; Sharma, S.; Cantor, A.; Gautam, A.; Haura, E.; Simon, G.; Sharma, A.; Sommers, E.; Robinson, L. RRM1 and PTEN as prognostic paramenters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22(10), 1878–1885.
   PubMed Web of Science ®Google Scholar
• Quinn, J.E.; Kennedy, R.D.; Mullan, P.B.; Gilmore, P.M.; Carty, M.; Johnston, P.G.; Harkin, D.P. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003, 63(19), 6221–6228.
   PubMed Web of Science ®Google Scholar
• Kennedy, R.D.; Quinn, J.E.; Mullan, P.B.; Johnston, P.G.; Harkin, D.P. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004, 96(22), 1659–1668.
   PubMed Web of Science ®Google Scholar
• Chabalier, C.; Lamare, C.; Racca, C.; Privat, M.; Valette, A.; Larminat, F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006, 5(9), 1001–1007.
   PubMed Web of Science ®Google Scholar
• Lafarge, S.; Sylvain, V.; Ferrara, M.; Bignon, Y.J. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001, 20(45), 6597–6606.
   PubMed Web of Science ®Google Scholar
• Oguri, T.; Achiwa, H.; Muramatsu, H.; Ozasa, H.; Sato, S.; Shimizu, S.; Yamazaki, H.; Eimoto, T.; Ueda, R. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett 2007, 256(1), 112–119.
   PubMed Web of Science ®Google Scholar
• Kim, S.O.; Jeong, J.Y.; Kim, M.R.; Cho, H.J.; Ju, J.Y.; Kwon, Y.S.; Oh, I.J.; Kim, K.S.; Kim, Y.I.; Lim, S.C.; Kim, Y.C. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 2008, 14(10), 3083–3088.
   PubMed Web of Science ®Google Scholar